Related Experiment Videos
[Calcium channel inhibitors and ventricular filling]
1Service de cardiologie clinique et expérimentale, CHU Rangueil, Toulouse.
Insights
Calcium channel blockers improve diastolic function in heart disease, particularly in ischemic and hypertrophic conditions. Their benefits in hypertensive heart disease are debated, likely due to vasodilatory effects rather than direct cardiac action.
Area of Science:
- Cardiology
- Pharmacology
- Physiology
Context:
- Ventricular diastolic dysfunction (relaxation and compliance) is an early indicator in various heart conditions.
- Calcium channel blockers (CCBs) show promise in improving diastolic function in specific cardiomyopathies.
- The efficacy of CCBs in secondary cardiac hypertrophy, like that from hypertension, is not well-established.
Purpose:
- To evaluate the role of calcium channel blockers in managing left ventricular diastolic dysfunction.
- To investigate the mechanisms underlying the effects of CCBs on diastolic function in different cardiac diseases.
Summary:
- Studies confirm CCBs benefit diastolic function in ischemic and primary hypertrophic cardiomyopathies.
- Evidence for CCB effectiveness in hypertensive heart disease (secondary hypertrophy) is controversial.
- Observed improvements in isovolumic relaxation and filling are primarily attributed to CCB-induced vasodilation, not direct myocardial effects.
Impact:
- Highlights the importance of vasodilation as a therapeutic mechanism for diastolic dysfunction.
- Suggests tailored approaches for CCB use based on the underlying cause of cardiac hypertrophy.
- Informs clinical practice regarding the management of heart failure with preserved ejection fraction.
Abstract:
Abnormalities of ventricular relaxation and compliance often precede changes in systolic function in ischemic and hypertrophic or hypertensive heart disease. Several studies using non-invasive methods have confirmed the beneficial effects of calcium channel blockers on left ventricular diastolic function in ischemic and primary hypertrophic cardiomyopathies. Their usefulness remains controversial in secondary cardiac hypertrophy such as in hypertensive heart disease. Improved left ventricular isovolumic relaxation and filling results more from the coronary and peripheral vasodilatory effects of calcium channel blockers than from a direct action on the cardiac muscle.